Celgene, Agios form new oncology deal, revise another

Celgene Corp. (NASDAQ:CELG) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) formed a new research collaboration to explore metabolic immuno-oncology. The companies also amended their 2010 cancer metabolism deal, returning to Agios worldwide rights to

Read the full 328 word article

User Sign In